Given that SPARC is a secreted protein, future studies to neutralize this matrikine through specific monoclonal antibodies may offer potential approaches to target NLRP3-driven inflammation and obesity-associated diseases. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.